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Background: Hepatitis C virus (HCV) is a human pathogen causing chronic liver disease in about 200 million
people worldwide. However, HCV resistance to interferon treatment is one of the important clinical implications,
suggesting the necessity to seek new therapies. It has already been shown that some forms of the catalytic RNA
moiety from E. coli RNase P, M1 RNA, can be introduced into the cytoplasm of mammalian cells for the purpose
of carrying out targeted cleavage of mRNA molecules. Our study is to use an engineering M1 RNA (i.e. M1GS)
for inhibiting HCV replication and demonstrates the utility of this ribozyme for antiviral applications.
Results: By analyzing the sequence and structure of the 5′ untranslated region of HCV RNA, a putative cleavage
site (C67-G68) was selected for ribozyme designing. Based on the flanking sequence of this site, a targeting M1GS
ribozyme (M1GS-HCV/C67) was constructed by linking a custom guide sequence (GS) to the 3′ termini of catalytic
RNA subunit (M1 RNA) of RNase P from Escherichia coli through an 88 nt-long bridge sequence. In vitro cleavage
assays confirmed that the engineered M1GS ribozyme cleaved the targeted RNA specifically. Moreover, ~85%
reduction in the expression levels of HCV proteins and >1000-fold reduction in viral growth were observed
in supernatant of cultured cells that transfected the functional ribozyme. In contrast, the HCV core expression
and viral growth were not significantly affected by a “disabled” ribozyme (i.e. M1GS-HCV/C67*). Moreover,
cholesterol-conjugated M1GS ribozyme (i.e. Chol-M1GS-HCV/C67) showed almost the same bioactivities with
M1GS-HCV/C67, demonstrating the potential to improve in vivo pharmacokinetic properties of M1GS-based
RNA therapeutics.
Conclusion: Our results provide direct evidence that the M1GS ribozyme can function as an antiviral agent and
effectively inhibit gene expression and multiplication of HCV.
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Hepatitis C virus (HCV), a member of the Flaviviridae
family, causes chronic liver disease in about 200 million
people worldwide. Its single-stranded RNA genome com-
prises a 5′ untranslated region (UTR), a long open reading
frame and a 3′-noncoding region, and functions as the
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unless otherwise stated.an internal ribosome entry site (IRES), while the open
reading frame encodes a polyprotein precursor (~3010
amino acids), which is cleaved into structural and non-
structural proteins [1]. HCV is known to cause persistent
infection and result in severe liver damages, including
cirrhosis, hepatic steatosis and hepatocellular carcinoma
[2]. Current clinical approaches are unable to provide sat-
isfactory therapy for HCV-infected patients. For example,
the combination of interferon-alpha with ribavirin and/or
viral protease inhibitors is effective only in 40% of infected
population [3]. Moreover, the efficacy of treatment usuallyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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novel antiviral agents and therapies are urgently needed.
Among the proposed antiviral agents are the ribozyme
derived from ribonuclease P (RNase P), which is a ribonu-
cleoprotein complex with ribozyme activity that catalyzes
a hydrolysis reaction to remove the leader sequence of
pre-tRNA and generate mature tRNA [5]. In Escherichia
coli, RNase P consists of an RNA subunit (M1 RNA) and
a protein subunit (C5 protein). The catalytic M1 RNA can
cleave the pre-tRNA substrate in vitro at high divalent ion
concentrations in the absence of C5 protein [6]. Moreover,
M1 RNA is able to cleave a target RNA sequence effi-
ciently if an additional small RNA is covalently linked to
the 3′ end of M1 RNA. The new sequence-specific ribo-
zyme is named M1GS ribozyme (Figure 1A) [7,8], and any
RNA could in principle be targeted by a custom-designed
M1GS for specific cleavage. When introduced into human
cells, M1GS ribozyme can function independently from
the endogenous human RNase P to cleave a targeting
sequence that base pairs with the guide sequence [9]. A
number of studies have shown that M1GS RNA and
RNase P are effective to cleave both viral and cellular
mRNAs and block their expression in cultured cells,
including inhibition of gene expression of human in-
fluenza, herpes viruses, human cytomegalovirus andFigure 1 Schematic representation of RNase P substrates. (A) A natura
RNA from E. coli, and a complex structure formed between a M1GS RNA an
are highlighted. The site of cleavage by RNase P or M1 RNA is marked with
study. The targeted sequence and guide sequence of the ribozyme are letthuman immunodeficiency virus [10-15]. Therefore,
M1GS-based strategy is not only a useful method in
basic research (e.g. regulation of gene expression) but
also represents a distinctive therapeutic approach of
nucleic-acid-based, sequence-specific interference [16].
By using RNase P as a tool, the genomic RNA of HCV
and the related animal pestiviruses has been previously
found to be directly processed in vitro by wild type RNase
P of either human origin or Synechocistis sp but not by the
wild type E. coli RNase P ribozyme (M1 RNA) [17-20].
Therefore, we attempt to use the M1GS ribozyme to
develop a new anti-HCV strategy and nucleic acid agent.
In this study, we chose the 5′ UTR of HCV genome as the
target region as it is relatively conserved and important
for the initiation of viral polyprotein translation [21]. We
show here that M1GS ribozyme was able to efficiently
cleave the target RNA sequence in vitro. Also about 85%
reduction of HCV core protein expression and ≥1000-fold
reduction of viral growth were observed in cells trans-
fected with the functional M1GS ribozyme.
Materials and methods
Viruses, cells and antibodies
HCV strain JFH1 (GT2a) was kindly provided by Dr.
Takaji Wakita (National Institute of Infectious Disease,l substrate (pre-tRNA), a small model substrate (GS:target RNA) for M1
d its RNA substrate. The structural components common to pre-tRNA
scissors. (B) The substrate and M1GS ribozyme constructed in this
ered in black and in blue, respectively.
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Francis Chisari (The Scripps Research Institute, California,
USA) and were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum
(FCS), 100 U/ml penicillin and 100 μl/ml streptomycin
sulfate. The monoclonal antibody MBS140205, which re-
acts with HCV core protein, was purchased from MyBio-
Source, Inc (San Diego, USA). The monoclonal antibody
against human GAPDH was purchased from Guangzhou
Whiga Technology Co., Ltd (Guangzhou, China).
Ribozyme and substrate constructs
By analyzing the sequence and structure of the 5′ UTR of
HCV RNA, a putative cleavage site (C67-G68) was selected
for designing ribozyme. Based on the flanking sequence of
this site, a targeting M1GS ribozyme (M1GS-HCV/C67)
was constructed by linking a custom guide sequence (GS)
to the 3′ termini of catalytic RNA. Plasmid pFL117, which
contains the DNA sequence encoding M1 RNA driven by
the T7 RNA polymerase promoter, was a gift from Prof.
Fenyong Liu (University of California, Berkeley). The
DNA sequences that encode ribozymes M1GS-HCV/C67
and M1GS-HCV/C67* were constructed by PCR using the
DNA sequence of M1 RNA as templates, with oligo-
nucleotides P1 (5′- CGGAATTCGAAGCTGACCAG
ACAG-3′) as the forward primers, and P2 (5′- CCCA
AGCTTGGTGTATAGCCATGGCTGTGGAATTGTG
AGCG-3′) and P2*(5′- CCCAAGCTTGGTGTATAGC
CATGGCAGGTGAAACTGACCGA-3′) as the reverse
primers, respectively. The two PCR products were
further inserted into the multiple cloning site of the
vector (pUC19) between the restriction sites EcoR I
and Hind III, and two recombinant plasmids containing
gene of M1GS ribozyme were constructed, i.e. pM1GS-
HCV/C67 and pM1GS-HCV/C67*, respectively. The DNA
sequence that encodes substrate S1–584 was constructed
by PCR using plasmid pGEM-HCJ4 (a gift from Prof.
Zhongtian Qi, The Second Military Medical University,
China) as template, and oligonucleotides P3 (5′-CGG
AATTCGCCAGCCCCCTGATGG-3′) and P4 (5′-CG
GGATCCGACGCCATCGCCGATGCGGGGCGATCC
TATAGTGAG-3′) as forward and reverse primers, re-
spectively. The PCR product was then inserted into the mul-
tiple cloning site of vector pGEM3z (between restriction
sites EcoR I and Hind III), and a recombinant plasmid con-
taining DNA sequence that encodes the substrate (S1–584)
was constructed, i.e. pGEM-S. Another irrelevant substrate,
segment of HCMV UL97 mRNA (1-600 nt), was selected as
a control of cleavage assay. The corresponding recombin-
ant plasmid was subcloned in a previous study [22].
In vitro cleavage by M1GS RNA
The M1GS RNAs and S1–584 RNA substrate were
synthesized in vitro with T7 RNA polymerase (TakaraBiotechnology Co., Ltd, Dalian, China) according to
the manufacture’s recommendations and purified on
8% urea/polyacrylamide gels. In addition, a cholesterol-
modified M1GS RNA (i.e. Chol-M1GS), which conjugated
a cholesterol molecule to the 5′ terminus of M1 RNA
through a pyrrolidine linker, was synthesized (Guangzhou
RiboBio Co., Ltd., China). Subsequently, the M1GS RNAs
(10 nM) were mixed with the [32P]-labeled RNA substrate
(10 nM). The cleavage reactions were carried out at 37°C
in a volume of 10 ul for 30 min in a buffer consisting of
50 mM Tris (pH 7.5), 100 mM NH4Cl and 100 mM
MgCl2. Reaction was stopped by the addition of 10 ul
solution containing 7 mol/L urea, 0.05% bromophenol
blue and 0.05% xylene cyanol. Cleavage products were
separated in denaturing gels and quantitated with a
Typhoon 9200 phosphorImager (Amersham Biosciences).
M1GS RNA internalization and viral infection
Huh7.5.1 cells were seeded at a density of 5.0 × 105 cells
per well in 6-well plates and grown to approximately
80% confluence prior to transfection. M1GS RNAs were
transfected into cells by using Lipofectamine 2000
reagent (Invitrogen). Lipofectamine 2000 reagent was
diluted in 100 μl of Opti-MEM medium with the
M1GS to give a final concentration of 10 μg/ml lipid-
100 nM M1GS RNA. The transfection experiments
were carried out by using 100 nM M1GS RNA. At 12 h
post-transfection, cells were serum starved for 12 h and
then infected (or mock-infected) by HCV (strain JFH1) at
a multiplicity of infection (MOI) of 1–5 in an inoculum of
1.5 ml DMEM supplemented with 1% FCS. After 2 h of
exposure to the virus at 37°C, the inoculum was replaced
with DMEM supplemented with 10% FCS.
Inhibition assay of viral gene expression by M1GS
ribozyme
To measure the inhibition of viral gene expression by
M1GS ribozyme, viral RNA and core protein were
detected by Northern blotting and Western blotting,
respectively. Cells were harvested at 48 h post-infection.
For Northern blotting, RNA extract was prepared as
described previously [22]. The RNA fractions were
separated in 1% agarose gels containing formaldehyde,
transferred to a nitrocellulose membrane, hybridized
with 32P-labeled DNA probes that contained the cDNA
sequences of HCV core coding region, M1 RNA gene or
human β-actin gene, and analyzed with a Typhoon 9200
PhosphorImager. The radiolabeled DNA probes were
used to detect HCV RNA (9.6 kb), M1GS RNAs (~0.48 kb)
and human β-actin mRNA, respectively. For Western
blotting, the cells were harvested and washed twice with
phosphate-buffered saline (PBS), and lysed in disruption
buffer consisting of 0.05 M Tris (pH 7.0), 8.5% (w/w) su-
crose, 5% (w/w) β-mercaptoethanol and 2% (w/w) sodium
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5 min before electrophoretic separation on 9% (w/w)
SDS-polyacrylamide denaturing gels cross-linked with N,
N’-methylenebisacylamide. The separated polypeptides
were transferred electrically to PVDF membranes and
reacted to the antibodies against HCV core protein
and human GAPDH. The membranes were subsequently
stained with a chemiluminescent substrate using a West-
ern chemiluminescent substrate kit (Bestbio Company,
Shanghai) and quantitated with a Typhoon 9200 phos-
phorImager. Quantitation was performed in the linear
range of protein detection.
Inhibition assays of viral growth by M1GS ribozyme
Huh7.5.1 cells (n =5 × 105) were infected with HCV at
an MOI of 1, and harvested at 4, 24, 36, 72 and 96 h
post-infection. The HCV RNA copies in the medium
were respectively determined by fluorescence quantita-
tive PCR, which was performed in a LightCycler 480
thermal cycler (Roche) under the following conditions:
heat activation of the polymerase for 5 min at 95°C,
followed by 40 cycles of 95°C for 15 sec, 55°C for 15 sec
and 72°C for 20 sec. The final melting curve was mea-
sured from 50°C to 95°C. The primers for HCV RNA were
5′-CGTTCTTGCGTCCTTCATCT-3′ (forward) and 5′-
CACAAAGTAGGGCTTGGTCAT-3′ (reverse). The pri-
mers for β-actin (internal standard) were 5′-TCGTCC
ACCGCAAATGCTTCTAG-3′ (forward) and 5′-ACTGC
TGTCACCTTCACCGTTCC-3′ (reverse).
Results
Construction of M1GS ribozymes
The 5′ UTR of HCV genomic RNA consists of 341 nucleo-
tides and folds to six secondary structure domains termed
SLI-VI. SLII, III and IV form an IRES that facilitates theFigure 2 Secondary structure of a portion of HCV 5′ UTR predicted by
arrows were potential cleavage sites of M1GS ribozyme. The site indicated
a yellow line capable of forming a long single-strand structure and facilitattranslation of capless HCV RNA [23]. IRES is present in a
highly organized conformation and associated with pro-
teins inside cells. In order to achieve efficient targeting, it
is pivotal to choose a targeting region which is accessible
to binding of ribozymes. Therefore, DNAMAN (v. 6) and
RNA structure (v. 4.5) softwares were used to analyze the
sequence and secondary structure of HCV 5′ UTR to
search for sequences with recognition and cleavage
features of M1GS ribozyme as characterized previously,
including requirement for a guanosine and a pyrimidine
to be the 3′ and 5′ nucleotides adjacent to the site of
cleavage, respectively [24]. It was found that three sites
were critical for the cleavage by M1GS ribozyme, and a
position 67 nucleotides downstream from the first nucleo-
tide of HCV genome was chosen as the cleavage site for
M1GS RNA because this site appears to be one of the
regions most accessible to HCV RNA in the 5′ UTR.
Moreover, the flanking sequence of the site also exhibited
several features needed to interact with an M1GS ribo-
zyme to achieve efficient cleavage (Figure 2).
According to the flanking sequence of the chosen site,
two M1GS ribozymes, i.e. M1GS-HCV/C67 and M1GS-
HCV/C67*, were constructed by covalently linking the 3′
termini of M1 RNA with a 13-nucleotide GS that was
complementary to the targeted RNA sequence. As
shown in Figure 3, M1GS-HCV/C67 contained a bridge
sequence between GS and M1 RNA, whereas M1GS-
HCV/C67* ribozyme had no bridge sequence – the same
GS was directly linked to the 3′ termini of M1 RNA
without a linker. Then the DNA fragments containing
M1GS genes were inserted in EcoR I/Hind III sites of
pUC19, and the two recombinant plasmids pM1GS-
HCV/C67 and pM1GS-HCV/C67* thus obtained were
determined by PCR and double endonuclease digestion,
and further verified by sequencing (data no shown). Tothe RNA Structure software. The three sites indicated by triangular
by scissors was an optimal cleavage site, with the sequence marked by
ing complementary binding with the GS sequence of M1GS ribozyme.
Figure 3 Schematic structure of the DNA sequences encoding M1GS ribozymes used in this study. (A) M1GS ribozyme with its guide
sequence (GS) directly linked to the 3′ terminus of M1 RNA. (B) M1GS ribozyme containing a bridge sequence, which is of 88 nt-length and links
a GS to the 3′ terminus of M1 RNA. (C) Cholesterol-modified M1GS ribozyme containing a cholesterol molecule to the 5′ terminus of M1 RNA,
with a bridge sequence between GS and M1 RNA.
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HCV/C67* were first Hind III-linearized and then syn-
thesized in vitro by T7 RNA polymerase. The transcripts
of M1GS-HCV/C67 and M1GS-HCV/C67* ribozymes
were confirmed to be 481 nt and 393 nt, respectively
(Figure 4).
In vitro cleavage activity of M1GS ribozymes
S1–584, a substrate containing the front 584 nucleotides
of HCV genomic RNA, was used to test the cleavage
activity of M1GS ribozymes (Figure 4 Lanes 8–10). The
ribozymes and RNA substrate were synthesized in vitro
and then incubated for ribozyme cleavage assays. No
cleavage of S1–584 was detected in the absence of M1GS
RNA (Figure 5 Lane 1), while efficient cleavage of the
substrate by M1GS-HCV/C67 or Chol-M1GS-HCV/C67
ribozyme yielding products of 67 and 528 nucleotidesFigure 4 Determination of M1GS ribozyme transcribed in vitro
by T7 RNA polymerase. The 32P-labeled M1GS RNAs and 32P-labeled
substrate RNA (S1–584) transcribed in vitro were separated on 15%
polyacrylamide gels containing 8 M urea.was observed (Figure 5 Lane 2 and 4). These results
demonstrate that M1GS-HCV/C67 was a functional
ribozyme and that cholesterol modification did not affect
the in vitro cleavage activity of the ribozyme. However,
cleavage of the same substrate by M1GS-HCV/C67*
ribozyme was barely detected (Figure 5 Lane 3), sug-
gesting M1GS-HCV/C67*, which contains the same
antisense GS as M1GS-HCV/C67 but is catalyticallyFigure 5 In vitro cleavage of the targeted RNA by M1GS
ribozymes. No ribozyme was added to the reaction mixture in lane
1; 10 nM of M1GS-HCV/C67 (lanes 2), M1GS-HCV/C67* (lanes 3) and
Chol-M1GS/C67 (lane 4) were incubated with
32P-labeled substrate
RNA (S1–584, 10 nM) at 37°C in a volume of 10 μl for 30 min in
cleavage buffer. As a control, equal volumes of M1GS-HCV/C67 and
Chol-M1GS-HCV/C67 were separately incubated with another
32P-labeled
substrate RNA (HCMV UL97 RNA) in the same condition (lanes 5 and 6)
Cleavage products were separated on 15% polyacrylamide gels
containing 8 M urea. The RNA makers were transcribed in vitro by T7
RNA polymerase with DNA templates linearized by different restriction
enzymes (lane M).
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in cultured cells.
Inhibition of HCV gene expression in M1GS-transfected cells
To determine whether M1GS ribozymes inhibit HCV
gene expression, Huh7.5.1 cells were first transfected
with M1GS RNAs and then infected with JFH1 at a
MOI of 5. Total cellular RNAs and proteins were pre-
pared from the infected cells at 48 h post-infection. The
levels of HCV RNA were determined by Northern
analysis, with the M1GS RNA and β actin mRNA as
internal controls (Figure 6B and C). Obvious reduction of
the HCV RNA levels was observed in cells transfected
with M1GS-HCV/C67 or cholesterol-conjugated M1GS-
HCV/C67 (Figure 6A, Lanes 4 and 5), while almost no
reduction was found in cells transfected with M1GS-
HCV/C67* (Figure 6A, Lane 3). Furthermore, more than
85% reduction of HCV core protein level in cells trans-
fected with M1GS-HCV/C67 or Chol-M1GS-HCV/C67
was also revealed by Western blotting with GAPDH as an
internal control (Figure 7, Lane 3 and 4), while no obvious
reduction was found in cells transfected with M1GS-
HCV/C67* (Figure 7, Lane 5).
Inhibition of viral growth by M1GS ribozyme
To test whether HCV growth is inhibited by ribozyme
transfection, cells were infected by JFH1 at an MOI of 1
and harvested at 4, 24, 36, 72 and 96 h post-infection.
Viral RNA copies in the culture medium at the indicated
times were determined. As shown in Figure 8, no signifi-
cant reduction was found in the cell cultures transfected
with M1GS-HCV/C67*, but >1000-fold reduction in viral
yield was observed in supernatant of cultured cells trans-
fected with M1GS-HCV/C67 or Chol-M1GS-HCV/C67
after 24 h of infection. These results suggest that M1GS-
mediated targeting of viral RNA effectively inhibits HCVFigure 6 Levels of HCV RNA as determined by Northern analysis. Cells
with JFH1 (MOI = 5) and harvested at 48 h after infection. Northern analysis
M1GS-HCV/C67* (lanes 3, 8 and 13), M1GS-HCV/C67 (lanes 4, 9 and 14), and
sample was separated on agarose gels containing formaldehyde, transferre
probe containing the cDNA sequences of HCV core coding region (A), M1growth and cholesterol modification on M1GS ribozyme
does not reduce its antiviral activity.
Discussion
RNase P is an essential ribonucleoprotein complex
found in all three domains of life. The RNase P holoen-
zyme is composed of an RNA subunit and one or more
protein subunits. The RNA component is the catalytic
moiety of RNase P across all phylogenetic domains, and
is responsible for the maturation of 5′ termini of all pre-
tRNAs, which account for about 2% of total cellular
RNA [25]. A unique feature of RNase P is its recognition
of substrate structures and thus is able to hydrolyze dif-
ferent natural substrates [26]. This is of great advantage
because recognition of structures rather than sequences
may help the fight against variable viruses as single or
even double mutations in the target sequence may well
be tolerated [27]. It is well known that HCV is highly
variable, and it has been proved that HCV genome can-
not be defined by a single sequence but by a population
of closely related variant sequences [28]. In consider-
ation of the “quasispecies” nature of HCV genome [29],
the RNase P-based M1GS ribozyme is a promising anti-
sense technique in HCV therapeutic studies.
HCV 5′ UTR is the most conserved locus within its
genome and thus efforts related to HCV RNA therapeu-
tics have been focused on this locus [30]. Nevertheless,
this region has a highly stable RNA structure and is
modulated by miRNAs and RNA-binding proteins,
which limits the number of accessible sites for ribozyme
targeting [31]. Therefore, it is important to select the
target regions from the 5′ UTR of HCV RNA that are
accessible to M1GS binding. In this study, we first ana-
lyzed the sequence of HCV 5′ UTR and found that three
sites, i.e. C20-G21, C67-G68 and U76-G77, met the general
features for M1GS cleavage activities [32]. All the three(n = 1 × 106) were either mock-infected (lanes 1, 6 and 11) or infected
was carried out with RNA isolated from Huh7.5.1 cells transfected with
Chol-M1GS-HCV/C67 (lanes 5, 10 and 15). Equal amount of each RNA
d to a nitrocellulose membrane, and hybridized to a 32P-radiolabeled
RNA gene (B), and human β-actin gene (C), respectively.
Figure 7 Levels of HCV core protein as determined by Western blot analysis. Cells were transfected with ribozymes or mock-transfected
and further infected with JFH1 (MOI = 5; lanes 1–5) for 48 h. Protein samples were separated on 9% polyacrylamide gels, transferred to membranes,
and analyzed with anti-HCV core protein and human GAPDH monoclonal antibodies.
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Further analysis on the secondary structure of this portion
with RNA structure software revealed that the 3′ flanking
sequence of the site C67-G68 formed a long single-strand
region but the flanking sequence of C20-G21 or U76-G77
folded into a stable stem-loop structure (Figure 2), while
the effect of long range annealing would make relevant
regions less accessible for targeting [33,34]. Therefore, the
region near C67-G68 may be more accessible for ribozyme
binding.
Based on the above putative site (C67-G68), a custom
guide sequence was designed, which was covalently
linked to the 3′ termini of M1 RNA through an 88 nt-
long bridge sequence, and a new targeting enzyme (i.e.
M1GS-HCV/C67) for the 5′ UTR of HCV RNA was suc-
cessfully constructed. In consideration of the influence
of bridge sequence on the cleavage activities of M1GS as
previously reported [35], a M1GS without a bridge, i.e.
M1GS-HCV/C67*, was also constructed as a control.
As shown in Figures 7 and 8, about 85% reduction of
the expression level of HCV core protein and >1000-foldFigure 8 Viral titers in supernatant of cultured cells that transfected w
of 1. The culture supernatants were then harvested at the indicated times.
real-time PCR method. Data shown were the means from triplicate experimreduction of viral growth were observed in supernatant
of cultured cells transfected with M1GS-HCV/C67 ribo-
zyme. On the other hand, no obvious reduction of the
levels of core gene expression and viral growth was
observed in cells transfected with M1GS-HCV/C67*.
Because M1GS-HCV/C67* contained an identical guide
sequence with M1GS-HCV/C67 and thus had a similar
binding affinity to target sequence. Therefore, the over-
all inhibition of viral gene expression and growth by
M1GS-HCV/C67 was mainly due to the targeted cleavage
by the ribozyme, as opposed to antisense or other nonspe-
cific effects of the guide sequence.
It has been reported that cholesterol-modified siRNAs
can be easily bound to human serum albumin, and thus
cholesterol modification has the potential to improve
in vivo pharmacokinetic properties of RNA therapeutics
and broaden their tissue biodistribution [36]. Therefore,
M1GS RNA was modified in this study with cholesterol
on the 5′ terminus of M1 RNA within the ribozyme,
and the cholesterol-conjugated M1GS ribozyme (i.e.
Chol-M1GS-HCV/C67) did not lose its cleavage activityith M1GS ribozyme. Huh7.5.1 cells were infected with JFH1 at a MOI
Quantitation of HCV titer was determined from viral RNA copies by
ents.
Mao et al. Virology Journal 2014, 11:86 Page 8 of 9
http://www.virologyj.com/content/11/1/86in vitro (Figure 5 Lane 4). Furthermore, similar to the
unconjugated M1GS RNAs, Chol-M1GS-HCV/C67 was
able not only to efficiently inhibit HCV gene expression
in transiently transfected Huh7.5.1 cells (Figure 6 Lane 5
and Figure 7 Lane 4) but also to significantly reduce
viral titers in the culture supernatant (Figure 8). To-
gether, our data demonstrate the successful use of an
M1GS ribozyme in the inhibition of HCV multiplication
and provide an insight into the potential of M1GS-base
therapeutics against HCV infection.
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